AUA: Flibanserin Shows Promise for Sexual Dysfunction in Females

Share this content:
AUA: Flibanserin Shows Promise for Sexual Dysfunction in Females
AUA: Flibanserin Shows Promise for Sexual Dysfunction in Females

MONDAY, May 15, 2017 (HealthDay News) -- Flibanserin (Addyi) may improve some measures of sexual dysfunction in premenopausal women, according to a study presented at the annual meeting of the American Urological Association, held from May 12 to 16 in Boston.

Researchers collected data on 2,360 premenopausal women who participated in three 24-week studies that compared flibanserin to an inactive placebo. All of the women had hypoactive sexual desire disorder. The response to the drug was measured using the Female Sexual Function Index.

The researchers found that, compared with a placebo, women taking a daily dose of flibanserin reported significant improvement in desire and the other areas of sexual function assessed by the index: arousal, lubrication, orgasm, satisfaction, and pain.

The drug is only approved by the U.S. Food and Drug Administration for premenopausal women, not postmenopausal women or men, according to a news release from the American Urological Association. The most common side effects are sleepiness and dizziness, but since the drug is taken before bedtime, these effects are usually not harmful. Other side effects include nausea, fatigue, insomnia, and dry mouth.

The research was funded by Valeant Pharmaceuticals North America, the maker of flibanserin.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Herbal and Dietary Supplements Are Commonly Mislabeled

Herbal and Dietary Supplements Are Commonly Mislabeled

Bodybuilding products have highest mislabeling rate; many mislabeled products tied to liver injury

Alcoholic Cirrhosis Linked to Increased Admissions, Costs

Alcoholic Cirrhosis Linked to Increased Admissions, Costs

Compared with non-alcoholic cirrhosis, excess 30-day readmissions total 29.2 per 100 patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »